Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials
Articolo
Data di Pubblicazione:
2007
Citazione:
Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials / M. Gheorghiade, M.A. Konstam, J.C. Burnett, L. Grinfeld, A.P. Maggioni, K. Swedberg, J. E. Udelson, F. Zannad, T. Cook, J. Ouyang, C. Zimmer, C. Orlandi, P. Agostoni. - In: JAMA. - ISSN 0098-7484. - 297:12(2007 Mar 28), pp. 1332-1343.
Abstract:
Heart failure causes more than 1 million US hospitalizations yearly, mostly related to congestion. Tolvaptan, an oral, nonpeptide, selective vasopressin V2-receptor antagonist, shows promise in this condition.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
Administration, Oral ; Heart Failure ; Double-Blind Method ; Benzazepines ; Humans ; Receptors, Vasopressin ; Diuretics ; Aged ; Cardiovascular Agents ; Furosemide ; Drug Therapy, Combination ; Hospitalization ; Aged, 80 and over ; Adult ; Middle Aged ; Male ; Female
Elenco autori:
M. Gheorghiade, M.A. Konstam, J.C. Burnett, L. Grinfeld, A.P. Maggioni, K. Swedberg, J. E. Udelson, F. Zannad, T. Cook, J. Ouyang, C. Zimmer, C. Orlandi, P. Agostoni
Link alla scheda completa: